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Abstract
Background: Few estimates exist of the life expectancy of HIV-positive adults receiving antiretroviral treatment (ART) in low-
and middle-income countries. We aimed to estimate the life expectancy of patients starting ART in South Africa and
compare it with that of HIV-negative adults.
Methods and Findings: Data were collected from six South African ART cohorts. Analysis was restricted to 37,740 HIV-
positive adults starting ART for the first time. Estimates of mortality were obtained by linking patient records to the national
population register. Relative survival models were used to estimate the excess mortality attributable to HIV by age, for
different baseline CD4 categories and different durations. Non-HIV mortality was estimated using a South African
demographic model. The average life expectancy of men starting ART varied between 27.6 y (95% CI: 25.2–30.2) at age 20 y
and 10.1 y (95% CI: 9.3–10.8) at age 60 y, while estimates for women at the same ages were substantially higher, at 36.8 y
(95% CI: 34.0–39.7) and 14.4 y (95% CI: 13.3–15.3), respectively. The life expectancy of a 20-y-old woman was 43.1 y (95% CI:
40.1–46.0) if her baseline CD4 count was$200 cells/ml, compared to 29.5 y (95% CI: 26.2–33.0) if her baseline CD4 count was
,50 cells/ml. Life expectancies of patients with baseline CD4 counts $200 cells/ml were between 70% and 86% of those in
HIV-negative adults of the same age and sex, and life expectancies were increased by 15%–20% in patients who had
survived 2 y after starting ART. However, the analysis was limited by a lack of mortality data at longer durations.
Conclusions: South African HIV-positive adults can have a near-normal life expectancy, provided that they start ART before
their CD4 count drops below 200 cells/ml. These findings demonstrate that the near-normal life expectancies of HIV-positive
individuals receiving ART in high-income countries can apply to low- and middle-income countries as well.
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Introduction
Estimates of life expectancies of HIV-infected individuals are
important in providing information to patients about their long-
term prognosis, in projecting the future costs of HIV-related care,
and in forecasting the likely future demographic and socioeco-
nomic impact of HIV/AIDS [1–3]. Several estimates of the life
expectancy of HIV-positive adults in high-income countries have
been published [4–13], and many of these studies have shown
dramatic improvements in life expectancy following the introduc-
tion of highly active antiretroviral treatment (ART). However,
only one previous study has directly estimated the life expectancy
of patients receiving ART in a low-income country [14]. The
dearth of estimates from low- and middle-income countries is a
reflection of both the later introduction of ART (with less time to
accumulate long-term survival data) and the problems associated
with obtaining accurate mortality estimates in these countries.
High rates of loss to follow-up [15], together with high mortality in
those lost to follow-up (LTFU) [16], mean that mortality is often
substantially underestimated. In the absence of reliable empirical
estimates, modellers have made conservative assumptions about
the life expectancy of adults starting ART in low- and middle-
income countries, typically around 10 y [17–19]. Uncertainty
regarding long-term HIV mortality is frequently manifested in
insurance companies’ refusal of life insurance applications by
HIV-positive individuals, or acceptance on very restrictive terms.
In South Africa there exists a unique opportunity to obtain
accurate estimates of ART mortality in a middle-income country
experiencing a generalised HIV epidemic. With around 90% of
adult deaths recorded through the country’s vital registration
system [20–23], South Africa is perhaps the only African country
with levels of vital registration high enough to permit independent
estimation of mortality rates in patients [24]. HIV/AIDS has had
a profound demographic impact in South Africa [20,25,26], but
access to ART has expanded rapidly since 2004, with ART
reaching almost 1.8 million South Africans by mid-2011 [27]. The
combination of high mortality ascertainment and large patient
numbers allows for greater precision in the estimation of ART
mortality than is possible in most low- and middle-income
countries. The objective of the present study is to estimate the
life expectancy of patients starting ART in South Africa, using
data from a large collaboration of ART programmes.
Methods
Cohort Description and Selection of Patients
The International Epidemiologic Databases to Evaluate AIDS
Southern Africa (IeDEA-SA) is a collaboration of ART pro-
grammes in southern Africa [28]. All IeDEA-SA programmes
obtained ethical approval from relevant local institutions before
contributing anonymised patient data to this collaborative analysis.
In addition, the collaboration obtained approval from the
University of Cape Town Human Research Ethics Committee
to receive and analyse these collaborative data. As all analyses
were performed with de-identified data, most patients did not
provide individual consent to participate in the study [28].
This analysis is limited to six programmes providing ART to
adults in South Africa [29,30]: the Aurum workplace treatment
programme, the Aurum community treatment programme, the
Hlabisa HIV treatment and care programme, the Khayelitsha
HIV treatment programme, McCord Hospital, and Themba
Lethu Clinic. The treatment centres are situated across three of
South Africa’s nine provinces (Western Cape, Gauteng, and
KwaZulu-Natal), mostly in urban areas, and most of the
programmes operate in the public health sector. Over the period
in which patients initiated ART (March 2001 to February 2010),
South African treatment guidelines in the public health sector
recommended that adult ART initiation be deferred until the
patient’s CD4 count was below 200 cells/ml or the patient had
progressed to World Health Organization clinical stage IV disease
[31]. We included patients who were aged 15 y or older at the
time of starting ART, were treatment-naı¨ve, and started ART in
2001 or later. Patients were excluded from the main analysis if
they had missing baseline CD4 values (no CD4 measurement
between 182 d before and 14 d after starting ART) or if their
baseline viral load was below 400 copies/ml (as these patients were
unlikely to be ART-naı¨ve).
Estimation of Mortality
We calculated observation time as starting at the time of ART
initiation and ending at the date of death or the date of analysis
closure, whichever occurred first. Patients were considered to be
LTFU if there was no record of their attendance at the clinic for at
least 182 d prior to database closure and their patient records did
not indicate that they had died. The date of database closure
differed for each of the participating programmes, and was
calculated as the last recorded visit date in each programme. The
date of analysis closure was defined for each programme to be the
date 182 d prior to the date of database closure, in order to allow
sufficient time to determine the LTFU status of each patient.
In the case of patients who were LTFU, the approach to
calculating person-years of observation (PYO) differed depending
on whether the programme had recorded the patient’s civil
identity document (ID) number and used this information to check
the vital status of the patient against the national population
register. In the case of LTFU patients with ID information, we
censored observation at the date of analysis closure or the date of
death recorded on the population register. Inverse probability
weighting was used to ensure that LTFU patients with IDs were
weighted up to represent the LTFU patients without IDs; this
meant assigning zero weight to the LTFU patients who had no ID
(so that the censoring dates for these patients were irrelevant) and
assigning weights equal to the inverse of the probability of having
ID information, in those patients who had IDs. This approach has
been used previously in estimating mortality rates in South African
patients receiving ART [21,32], and is analogous to the weighting
methods that are commonly used to correct for non-informative
censoring through double sampling [33]. Inverse probability
weights were calculated by applying separate logistic regression
models to the LTFU patients in each cohort, to predict the
probability of having recorded ID information.
In one of the cohorts, problems with the recording of date of last
clinic attendance prevented us from applying the LTFU definition
and using inverse probability weighting. In this cohort, analysis
was restricted to those patients with IDs, and observation time was
censored at the date of death or date of analysis closure (the latter
being defined as the date 30 d prior to when the national
population register was last checked). In a sensitivity analysis we
considered the effect of applying the same method to all of the
other cohorts.
Statistical Methods
We used a relative survival approach to model the excess
mortality attributable to HIV, relative to non-HIV mortality rates
in South Africa, over different durations from ART initiation
[34,35]. The relative survival model was applied separately to
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male and female mortality data, allowing for four covariates: age,
cohort, number of years since ART initiation, and CD4 category
at ART initiation (Figure S1). HIV-associated mortality was
assumed to be an exponential function of age, based on an
examination of standardised mortality rates in each 5-y age
interval (Figure S2). We grouped individuals into one of four
baseline CD4 categories: ,50, 50–99, 100–199, and $200 cells/
ml. Mortality rates were assumed to be constant over each integer
age and integer duration. We defined four duration categories: the
first 12 mo after starting ART, months 13–24 after starting ART,
months 25–36 after starting ART, and more than 36 mo after
starting ART. The model was fitted separately for the first 12 mo
and durations longer than 12 mo, to allow for differences in the
effect of age, CD4 count, and cohort at different durations. A
more detailed mathematical description of the model is provided
in section 1 of Text S1.
We obtained estimates of non-HIV mortality, by age and sex,
from an independent demographic model of the South African
population [36] and used these mortality rates to calculate the life
expectancy of HIV-negative individuals, for comparison purposes.
The demographic model derives non-HIV mortality rates based
on a modification of the Brass logit life table system, which takes
into account estimates of South African mortality prior to the
AIDS epidemic, changes over time in recorded numbers of deaths,
and modelled estimates of trends in AIDS mortality (a more
detailed explanation of the method is provided in section 2 of Text
S1).
We fitted the relative survival model to the data using a
maximum likelihood approach in STATA 11.0 (StataCorp),
assuming that the number of deaths in each age, sex, cohort,
CD4, and duration category was Poisson-distributed. Parametric
bootstrapping was used to generate 1,000 alternative parameter
estimates [37]. We developed a C++ programme to calculate the
life table and life expectancy for various combinations of age, sex,
cohort, and baseline CD4 categories. The programme was also
used to estimate the fraction of patients starting ART who were
expected to die from causes unrelated to HIV. We ran this
programme for each of the 1,000 bootstrap-sampled parameter
estimates to generate distributions of life expectancy estimates, and
calculated means and 95% confidence intervals from these.
Results obtained for individual cohorts were averaged for the
purpose of presenting overall results. Mathematical details
regarding the model fitting procedure and life expectancy
calculations are included in sections 3–5 of Text S1.
Sensitivity Analyses
To assess the sensitivity of the results to the high early mortality
after ART initiation, we estimated life expectancy for patients who
had survived 24 mo since ART initiation. We also limited the
analysis to patients with IDs, to assess the effect of longer follow-up
time (with later administrative censoring), and also to assess the
effect of not applying inverse probability weighting in LTFU
patients. To assess sensitivity to non-HIV mortality rates, the
relative survival model was refitted after increasing the assumed
non-HIV mortality rates by 50%. In addition, we refitted the
model using a negative binomial model in place of the Poisson
model, to assess possible bias due to over-dispersion [38]. To assess
the effect of including patients with missing baseline CD4 values,
we repeated the analysis after assigning CD4 values to these
patients using multiple imputation [39].
Because the relative survival approach differs substantially from
the more widely used abridged life table method, we also estimated
life expectancy using the abridged life table approach [40,41].
Mortality rates were calculated in each 5-y age band, stratified by
sex and baseline CD4 category but not by duration. Because of the
small number of patients at older ages, all observations at age 55 y
and above were grouped together in a single upper age interval,
consistent with the approach adopted in other abridged life table
studies [9,11,14]. Confidence intervals were calculated using
bootstrapping.
Results
Analysis was based on 37,740 adults who started ART between
March 2001 and February 2010. Table 1 shows the patient
characteristics at the time of ART initiation. Relatively few
patients were aged 55 y or older (3.7%), and relatively few patients
had CD4 counts$200 cells/ml (13.2%). Following ART initiation,
2,066 deaths were recorded in patient record systems, and 16,250
patients were LTFU or were considered to have unreliable
information regarding their last visit date. Of the 16,250, 13,968
had a recorded ID, and in these patients with ID, 2,947 deaths
were identified in the population register. After including deaths
recorded in the population register and applying the inverse
probability weighting to the LTFU patients, there were 5,782
deaths during 69,514 person-years, for a mean follow-up of 1.84 y
(median 1.69 y). The mortality rate was 83.2 per 1,000 PYO, and
was substantially higher in males (99.8 per 1,000 PYO) than in
females (72.6 per 1,000 PYO). Although mortality rates were high
during the first 12 mo after starting ART, mortality rates reduced
to low levels at longer durations (Figures S1 and S2). The
estimated parameters of the model of HIV mortality are included
in section 6 of Text S1.
Table 2 summarises the model estimates of life expectancies at
ART initiation. The most significant factor determining life
Table 1. Patient characteristics at start of ART.
Characteristic n Percent
Sex
Male 14,528 39.5%
Female 23,212 61.5%
Age
15–24 y 2,697 7.1%
25–34 y 15,584 41.3%
35–44 y 12,699 33.6%
45–54 y 5,357 14.2%
55+ y 1,403 3.7%
CD4 count
,50 cells/ml 10,411 27.6%
50–99 cells/ml 7,642 20.2%
100–199 cells/ml 14,689 38.9%
$200 cells/ml 4,998 13.2%
Year of ART initiation
2001–2003 913 2.4%
2004 3,079 8.2%
2005 6,122 16.2%
2006 9,683 25.7%
2007 8,630 22.9%
2008 5,956 15.8%
2009–2010 3,357 8.9%
doi:10.1371/journal.pmed.1001418.t001
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expectancy of treated patients was age at ART initiation; the
average life expectancy of men starting ART varied between
27.6 y (95% CI: 25.2–30.2) at age 20 y and 10.1 y (95% CI: 9.3–
10.8) at age 60 y, while corresponding estimates in women were
36.8 (95% CI: 34.0–39.7) and 14.4 (95% CI: 13.3–15.3),
respectively. Life expectancies were also significantly influenced
by baseline CD4 counts; life expectancies in patients with baseline
CD4 counts $200 cells/ml were between 70% (95% CI: 62%–
77%) and 86% (95% CI: 81%–90%) of those in HIV-negative
adults of the same age and sex, while patients starting ART with
CD4 counts of ,50 cells/ml had life expectancies that were
between 48% (95% CI: 43%–55%) and 61% (95% CI: 54%–67%)
of those in HIV-negative adults (Figure 1).
Figure 2 shows the estimated fraction of patients starting ART
who are expected to die from causes unrelated to HIV, if non-HIV
mortality rates are the same in ART patients as they are in the
HIV-negative population. This fraction was higher at older ages
(up to 68% [95% CI: 58%–77%] in men and 80% [95% CI:
72%–87%] in women), as the estimated mortality rates in the
HIV-negative population increased more steeply with respect to
age than the excess HIV mortality rates in ART patients. The
fraction was also higher in women than in men, because HIV-
related mortality increased more steeply with respect to age in men
than in women (Table 1 of Text S1).
Life expectancies differed substantially between cohorts. For
men starting ART at age 35 y, life expectancy varied between
16.6 y (95% CI: 14.4–19.2) and 28.6 y (95% CI: 26.2–30.3). Life
expectancy in women starting ART at age 35 y varied between
23.6 y (95% CI: 21.4–25.9) and 35.5 y (95% CI: 33.3–36.9). The
average life expectancies in Table 2 were closest to those of the
public sector programmes operating in urban areas.
In the sensitivity analysis that included only patients with
recorded ID (n= 30,287), total PYO increased (83,199 PYO) and
average follow-up time increased (2.75 y) because of the later
analysis closure date. In these patients, 1,451 deaths were recorded
through patient record systems, and a further 3,760 were identified
through the national population register, yielding a crude
mortality rate of 62.6 per 1,000 PYO. Modelled mortality rates
were lower in patients starting ART after 2006 than in patients
starting ART in 2006 or earlier, and life expectancies were
therefore calculated separately for the two enrolment periods.
Women with recorded ID who started ART in 2006 or earlier had
similar life expectancies to those in the main analysis, but men
with recorded ID who started ART in 2006 or earlier had life
expectancies about 12% higher than those in the main analysis
(Table 3). Life expectancies in patients with IDs who started ART
after 2006 were in turn higher than those in patients with IDs who
started ART before or in 2006 (Table 3; Figure 3). In the subset of
these patients starting ART after 2006 with baseline CD4 counts
$200 cells/ml, life expectancies were between 82% (95% CI:
77%–87%) and 88% (95% CI: 84%–91%) of those in HIV-
negative individuals of the same age and sex.
Further sensitivity analyses are presented in Table 3. Estimates
of life expectancy in patients who had survived 24 mo after
starting ART were 15%–20% higher than those in patients of the
same age who had just started ART. The use of the abridged life
table method led to substantially lower estimates of life expectancy
in patients starting ART at young ages, compared with the relative
survival approach; the differences between the abridged life table
and relative survival estimates were less substantial in patients
starting ART at older ages. The use of multiple imputation to
assign baseline CD4 values to individuals with missing information
led to almost no change in life expectancy. The use of negative
binomial models in place of Poisson models also produced almost
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identical model results. After refitting the model with 50% higher
non-HIV mortality rates, life expectancy estimates were reduced
by 1–2 y. Further comparison of different model estimates by CD4
strata is included in sections 7–12 of Text S1.
Discussion
This analysis shows that South African patients starting ART
have life expectancies around 80% of normal life expectancy,
provided that they start treatment before their CD4 count drops
below 200 cells/ml. Life expectancies are also 15%–20% higher in
patients who have survived to 24 mo after starting ART than in
patients of the same age who have just started therapy. Although
these results are encouraging, programmes in resource-limited
settings experience major challenges with late diagnosis, low
uptake of CD4 testing, loss from pre-ART care, and delayed ART
initiation [42]. Individuals who start ART also frequently interrupt
treatment in the South African setting [43], and these interrup-
tions are often associated with poorer immunological recovery and
the development of drug resistance [44]. Health services need to
overcome these challenges if near-normal life expectancies are to
be achieved for the majority of HIV-positive South Africans.
South African treatment guidelines have recently changed, and
it is now recommended that all HIV-infected adults should start
ART when their CD4 counts fall below 350 cells/ml. Recent
campaigns to increase the uptake of HIV testing [45] combined
with dramatic growth in rates of ART enrolment in South Africa
[27] should lead to a substantially increased proportion of patients
starting ART at CD4 counts above 200 cells/ml. However, over
the period to which this analysis relates, most of the patients
starting ART at CD4 counts above 200 cells/ml did so because
they qualified for treatment on clinical grounds. Such patients are
likely to experience higher mortality than asymptomatic patients
with CD4 counts above 200 cells/ml [46,47]. These estimates of
life expectancy for adults who have initiated ART with CD4
counts above 200 cells/ml may therefore be underestimates of the
life expectancies in future, when a greater fraction of such
individuals are likely to be asymptomatic.
A key strength of this analysis is that it incorporates data from
the South African population register to obtain more accurate
Figure 1. Life expectancies of patients starting ART, as proportions of life expectancies of HIV-negative adults. Proportions are plotted
by age at ART initiation and baseline CD4 count, for men (A) and women (B). Bars represent means, and error bars represent 95% confidence intervals.
doi:10.1371/journal.pmed.1001418.g001
Figure 2. Proportion of individuals starting ART who are expected to die from causes unrelated to HIV. Proportions are plotted by age
at ART initiation and baseline CD4 count, for men (A) and women (B). Bars represent means, and error bars represent 95% confidence intervals.
doi:10.1371/journal.pmed.1001418.g002
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estimates of mortality than are usually possible in African
countries. Because patients with ID information are not censored
at the date of loss to follow-up, these estimates of life expectancy
are inclusive of patients who are not retained in care. However,
there is likely to be a small proportion of deaths (probably around
5%) that are recorded neither in the patient record system nor in
the vital registration system. Although this figure is lower than the
proportion of deaths missing from the vital registration system
because of the added information from patient record systems, it
may nevertheless lead to life expectancies of ART patients being
slightly exaggerated.
Predicting future mortality for HIV-positive patients on ART is
challenging. In addition to the historical bias towards enrolment of
symptomatic patients, mentioned previously, our mortality
estimates do not take into account potential future reductions in
mortality that may occur as new drugs and salvage regimens [48]
and innovations in patient management are introduced [49]. In
the sensitivity analysis that was limited to patients with recorded
IDs, we found higher life expectancies in patients who started
ART after 2006 than in patients starting ART in or before 2006.
This result may be due to a change in the disease severity of
patients starting ART over time (a factor that we have not fully
controlled for) or possibly improvements in regimen options and
patient management.
A limitation of this analysis is the short average duration of
follow-up (1.84 y), which we have addressed by controlling for
differences in mortality by duration. Our method of controlling for
differences by duration is based on the assumption that mortality
rates are piecewise constant over 1-y duration intervals. To the
extent that there is residual variation in mortality by duration, for
which we have not fully controlled, our method will be biased
towards overestimating mortality when the average follow-up time
is short, because the observation time in each duration interval will
be weighted toward the lower end of the interval, where mortality
rates are likely to be highest. This bias is evident when comparing
the results from the main analysis with the results from the analysis
that is limited to patients with IDs; the longer average follow-up
time (2.75 y) leads to slightly lower mortality rates over each
duration interval (results not shown) and hence increased life
expectancies. Due to the small number of patients on ART at long
durations, mortality data have been aggregated for all durations
greater than 36 mo. This approach may be reasonable, as average
CD4 counts tend to stabilise after the first 36 mo of treatment
[50,51]. However, if HIV-related mortality continues to decline
with increasing duration, the lack of data at long durations could
result in some underestimation of life expectancy. On the other
hand, the accumulation of drug resistance mutations at longer
durations could cause long-term increases in HIV-related mortal-
ity, and mathematical modelling suggests that life expectancy may
be sensitive to the number of treatment options available [52].
The principle advantage of the relative survival model,
compared with the abridged life table method that is more
commonly used in the estimation of life expectancy, is that it
adjusts for differences in mortality by duration, which are
particularly marked in resource-limited settings [53]. Although
both of the measures presented here are period life expectancies
rather than cohort life expectancies [54], controlling for differ-
ences in mortality by duration yields average survival times closer
to those that might be expected in actual cohorts of patients
initiating ART. Not controlling for duration means that the life
expectancies represent the expected survival if age-specific
mortality rates in the future were to remain unchanged at the
high average levels measured between 2001 and 2010, which
means that the abridged life table method gives too much weight
to the high mortality rates soon after ART initiation. Another
advantage of the relative survival approach is that it incorporates
information on non-HIV mortality in the general population,
which is likely to be relatively more significant at older ages. This
analysis suggests that a substantial proportion of deaths in ART
patients are likely to be unrelated to their HIV infection. It is
therefore important that comparisons of life expectancies of HIV
patients in different regions take into account differences in non-
HIV mortality between settings, and the relative survival model
provides a framework within which this comparison can be
achieved.
Studies of life expectancies of ART patients in high-income
countries that have excluded high-risk groups (people who inject
drugs and patients starting ART in advanced disease) have
generally estimated life expectancies that are 73%–99% of those in
the general population [4,7,12,55]. However, studies that have not
excluded high-risk groups have estimated life expectancies that are
51%–66% of those in the general population [5,12,56]. These
results are roughly consistent with our ratios: 62%–75% when all
CD4 categories are combined, and 70%–86% when analysis is
Figure 3. Life expectancies of patients with recorded ID, starting ART after 2006. Life expectancies are plotted by age at ART initiation and
baseline CD4 count, for men (A) and women (B). Bars represent means, and error bars represent 95% confidence intervals.
doi:10.1371/journal.pmed.1001418.g003
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restricted to patients with baseline CD4 counts $200 cells/ml
(Figure 1). Our ratios become even higher (87%–96%) when
considering patients who started ART with CD4 counts $200
cells/ml and who survived their first 2 y after ART initiation.
Only one other study in Africa has estimated the life expectancy
of patients starting ART [14]. This study, conducted in Uganda,
estimated lower life expectancy in patients starting ART at young
ages, compared with our South African estimates, but generated
higher estimates than those obtained in South Africa for patients
starting ART at older ages. These differences may be partly
attributable to differences in methodology, as Table 3 shows that
the abridged life table method (used in the Ugandan study) is likely
to generate lower estimates of life expectancy at younger ages.
Some of the difference may also be attributable to differences in
baseline CD4 counts, which were generally higher in Uganda (the
proportion with baseline CD4 count $100 cells/ml was 65%,
compared to 52% in South Africa). Some of the difference may
also be explained by differences in the approach to determining
the mortality of patients LTFU, which was assumed to be 30% in
the Ugandan analysis.
The generalisability of our findings—even within South
Africa—is open to question. The South African cohorts partici-
pating in the IeDEA-SA Collaboration are relatively well-
resourced programmes with substantial research support, mostly
in urban centres. Life expectancies differed between cohorts
because of differences in patients’ socioeconomic characteristics as
well as differences in models of ART delivery. The average results
that we have presented are likely to be typical of public sector
programmes in urban areas, but mortality rates may differ in rural
treatment programmes and in private sector programmes. The
assumption that the average non-HIV mortality rates in South
Africa apply in all cohorts could also be problematic, although
estimates of life expectancy did not change substantially when the
model was refitted with 50% higher non-HIV mortality rates.
These findings might not be typical of programmes in most other
African countries, as South Africa is an upper middle-income
country with rates of non-HIV mortality lower than in most other
African countries [57]. HIV-related mortality in South African
ART patients may also be lower than in other African countries
due to virological monitoring of ART patients, which is routine in
South Africa but not in most other African countries [58].
These results have important implications for the pricing models
used by life insurance companies, as well as the demographic and
epidemiological models that are used to forecast the impact and cost
of ART programmes in low- and middle-income countries. These
models have typically assumed that life expectancy after ART
initiation is around 10 y [17–19]. Assumptions of longer life
expectancy would significantly reduce the forecasts of AIDS
mortality, but would also significantly increase long-term projections
of numbers of patients receiving ART. With the anticipated increase
in the fraction of patients starting ART at higher CD4 counts in
future, long-term survival can be expected to increase even further. It
is therefore critical that appropriate funding systems and innovative
ways to reduce costs are put in place, to ensure the long-term
sustainability of ART delivery in low- and middle-income countries.
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Figure S1 Cumulative survival after ART initiation,
compared to age-standardised survival rates in the
HIV-negative population. HIV-positive survival curves are
calculated by grouping all ages and cohorts together and applying
Kaplan-Meier methods to calculate proportions surviving, after
including data from the national population register and applying
inverse probability weighting. HIV-negative survival curves are
calculated for a hypothetical cohort with the same initial age
distribution as the HIV-positive cohort.
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Figure S2 Annual mortality rates stratified by age, sex,
and time since ART initiation. Dots represent observed
mortality rates, standardised to the CD4 distribution in Table 1
and calculated over 5-y age groups. Vertical lines represent 95%
confidence intervals.
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Editors’ Summary
Background. According to the latest figures, more than 34
million people worldwide currently live with HIV/AIDS. In
2011, an estimated 2.5 million people were newly infected
with HIV, and in the same year 1.7 million people died from
AIDS. Since the beginning of the epidemic in the 1980s,
more than 60 million people have contracted HIV and nearly
30 million have died of HIV-related causes. Despite the stark
statistics, the life expectancy for people infected with the
AIDS virus has dramatically improved over the past decade
since the introduction of an effective combination of
antiretroviral drugs. In high-income countries, people who
are HIV-positive can expect a near-normal life expectancy if
they take these drugs (as antiretroviral treatment—ART)
throughout their life.
Why Was This Study Done? Recent studies investigating
the life expectancy of people living with HIV have mostly
focused on the situation in high-income settings. The
situation in low- and middle-income countries is vastly
different. People who are diagnosed with HIV are often late
in starting treatment, treatments regimes are sometimes
interrupted, and a large proportion of patients are lost to
follow-up. It is important to gain a realistic estimate of life
expectancy in low- and middle-income countries so patients
can be given the best information. So in this study the
researchers used a model to estimate the life expectancy of
patients starting ART in South Africa, using data from several
ART programs.
What Did the Researchers Do and Find? The researchers
used data collected from six programs in South Africa based
in Western Cape, Gauteng, and KwaZulu-Natal between 2001
and 2010. The researchers calculated the observation time
from the time of ART initiation to the date of death or to the
end of the study. Then the researchers used a relative
survival approach to model the excess mortality attributable
to HIV, relative to non-HIV mortality rates in South Africa,
over different periods from ART initiation.
Using these methods, the researchers found that over the
time period, 37,740 adults started ART and 2,066 deaths
were recorded in patient record systems. Of the 16,250
patients who were lost to follow-up, the researchers
identified 2,947 further deaths in the population register.
When they inputted these figures into their model, the
researchers estimated that the mortality rate was 83.2 per
1,000 person-years of observation (PYO), and was higher in
males (99.8 per 1,000 PYO) than in females (72.6 per 1,000
PYO). The researchers also found that the most significant
factor determining the life expectancy of treated patients
was their age at ART initiation: the average life expectancy
of men starting ART varied between 27.6 years at age 20
and 10.1 years at age 60, while corresponding estimates in
women were 36.8 and 14.4, respectively. Life expectancies
were also significantly influenced by baseline CD4 counts;
life expectancies in patients with baseline CD4 counts
$200 cells/ml were between 70% and 86% of those of HIV-
negative adults of the same age and sex, while patients
starting ART with CD4 counts of ,50 cells/ml had life
expectancies that were between 48% and 61% of those of
HIV-negative adults. Importantly, the researchers found
that life expectancies were also 15%–20% higher in
patients who survived their first 24 months after starting
ART than in patients of the same age who had just started
therapy.
What Do These Findings Mean? These findings suggest
that in South Africa, patients starting ART have life
expectancies around 80% of normal life expectancy, provid-
ed that they start treatment before their CD4 count drops
below 200 cells/ml. Although these results are encouraging,
this study highlights that health services must overcome
major challenges, such as dealing with late diagnosis, low
uptake of CD4 testing, loss from pre-ART care, and delayed
ART initiation, if near-normal life expectancies are to be
achieved for the majority of HIV-positive South Africans. With
the anticipated increase in the fraction of patients starting
ART at higher CD4 counts in the future, long-term survival
can be expected to increase even further. It is therefore
critical that appropriate funding systems and innovative
ways to reduce costs are put in place, to ensure the long-
term sustainability of ART delivery in low- and middle-
income countries.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001418.
N The International Epidemiologic Databases to Evaluate
AIDS has more statistical information from world regions
N amfAR, the Foundation for AIDS Research, works with
health care workers and AIDS organizations in developing
countries to create and implement effective HIV research,
treatment, prevention, and education strategies
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